case_images: PMC4657800_01
case_images: PET/CT scans prior to and during regorafenib treatment.. Notes: (A) Abdominal PET scan before initiation of regorafenib, with right pleural-based mass (green box) measuring 27.6 mm, 14.4 max standardized uptake value (SUV); (B) five months after therapy, with same right pleural-based mass (green box) measuring 26.7 mm, 3.4 max SUV.. Abbreviations: PET, positron emission tomography; CT, computed tomography.
case_images: cmar-7-357Fig1.jpg
case_images: PMC4657800_01_cmar-7-357Fig1.jpg
case_images: f1-cmar-7-357
case_images: The patient continued with cetuximab and FOLFIRI until August 2013, and a repeat PET/CT scan in September 2013 revealed progressive disease in the right pleural mass along with increase in size of the retrocrural and left inguinal lymph nodes and liver (Figure 1A). A repeat PET/CT scan in February 2014 showed a mixed response, with increased activity in non-target lesions noted in multiple omental, peritoneal, and pelvic lesions, but decreased activity in target lesions, specifically the thoracic and liver lesions, with new activity in the right tenth rib (Figure 1B).